期刊文献+

4-甲氧基-3-(3-吗啉-4-基丙氧基)苯甲腈的合成工艺

Synthetic Process of 4-Methoxy-3-(3-morpholinopropoxy) benzonitrile
下载PDF
导出
摘要 以异香兰素和盐酸羟胺为起始原料,脱水得到3-羟基-4-甲氧基苯腈;再与N-(3-氯丙基)吗啉经烷基化反应制得4-甲氧基-3-(3-吗啉-4-基丙氧基)苯甲腈。产物结构经IR和NMR表征。经单因素实验,确定合成3-羟基-4-甲氧基苯腈的最优条件为n(异香兰素)∶n(盐酸羟胺)=1∶2,乙腈为溶剂,反应温度为72℃,反应时间6 h,收率为96%;确定合成4-甲氧基-3-(3-吗啉-4-基丙氧基)苯甲腈的最优条件为n(3-羟基-4-甲氧基苯腈)∶n[N-(3-氯丙基)吗啉]=1.0∶1.1,乙腈为溶剂,回流反应6 h,收率为96%。经过两步优化,高产率获得目标化合物,后处理简单,更适合工业化生产。 3-Hydroxy-4-methoxybenzonitrile was synthesized from isovanillin and hydroxylamine hydrochloride by dehydration. And then 4-methoxy-3-( 3-morpholinopropoxy) benzonitrile was synthesized by alkylation of 3-hydroxy-4-methoxybenzonitrile with 4-( 3-chloropropyl) morpholine. The structures of product were characterized by IR and nuclear magnetic resonance( NMR). The optimum reaction conditions for the synthesis of 3-hydroxy-4-methoxybenzonitrile were as follows: n( isovanillin) ∶ n( hydroxylamine hydrochloride) =1∶2,acetonitrile as solvent,reaction temperature 72 ℃,reaction time 6 hours. Under these conditions,the yield of 3-hydroxy-4-methoxybenzonitrile reached 96%. The yield of 4-methoxy-3-( 3-morpholinopropoxy) benzonitrile reached 96% under the optimum reaction conditions of n( 3-hydroxy-4-methoxybenzonitrile) ∶n[N-( 3-chloropropyl) morpholine]=1. 0∶1. 1,acetonitrile as solvent,reaction time 6 hours at reflux temperature. After two steps of optimization,the target compound with high yield was obtained. The post-treatment is simple and more suitable for industrial production.
出处 《精细化工》 EI CAS CSCD 北大核心 2018年第3期525-528,共4页 Fine Chemicals
基金 江苏省前瞻性联合研究项目(BY2016066-02)~~
关键词 4-甲氧基-3-(3-吗啉-4-基丙氧基)苯甲腈 吉非替尼 异香兰素 医药原料 4-methoxy-3- (3-morpholinopropoxy) benzonitr/le gefitinib isovanillin drug materials
  • 相关文献

参考文献6

二级参考文献53

  • 1张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 2金波,陈国华,邹爱峰,石涛,任金山.吉非替尼的合成[J].中国药科大学学报,2005,36(1):92-94. 被引量:11
  • 3张竹霞,吕荣文,张珂珂,高昆玉.水合肼还原芳硝基物的研究[J].精细化工,2001,18(4):239-242. 被引量:54
  • 4常涛,梅丹,张力,李大魁.新型抗肿瘤药物——吉非替尼[J].中国药学杂志,2006,41(12):958-959. 被引量:16
  • 5Schlesinger J.Cell signaling by receptor tyrosine kinases[J].Cell,2000,103,211-225.
  • 6Hubbard R D,Bamaung N Y,Fidanze S D,et al.Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases[J].Bioorg.Med.Chem.Lett.2009,19,1718-1721.
  • 7Rheault T R,Caferro T R,Dickerson S H,et al.Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors[J].Bioorg.Med.Chem.Lett.,2009,19,817-820.
  • 8Frampton J E,Easthope S E.Gefitinib[J].Drugs,2004,64(21):2475-2492.
  • 9Gibson K H.Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors:WO,9633980[P].1996-10-31.
  • 10Li M D,Zheng Y G,Ji M.Synthesis of Gefitinib from Methyl 3-Hydroxy-4-methoxy-benzoate[J].Molecules,2007,12,673-678.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部